Evommune's stock nearly doubles after successful eczema treatment release, potentially challenging Dupixent.
On Tuesday, the IPO stock Evommune soared by approximately 100%, following encouraging outcomes for its intravenous eczema therapy. The question arises if Dupixent, a well-known eczema treatment, may face strong competition from Evommune.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments